SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $171

BMO Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $145 to $171.

Benzinga · 05/07/2020 16:53

BMO Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $145 to $171.